Company

Hybio Pharmaceutical's HY3003 Clears FDA IND – Triple GLP‑1R/GIPR/GCGR Agonist Advances Toward the Obesity Market
Clinical trial approval / initiationHot targets

Hybio Pharmaceutical’s HY3003 Clears FDA IND – Triple GLP‑1R/GIPR/GCGR Agonist Advances Toward the Obesity Market

Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced that its investigational drug HY3003 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), clearing the way…

Hinova Licenses Oral VAV1 Molecular Glue Degrader HP570 to Evommune in Up to USD 1.1 Billion Deal – Days After FDA IND Clearance for Rheumatoid Arthritis

Hinova Licenses Oral VAV1 Molecular Glue Degrader HP570 to Evommune in Up to USD 1.1 Billion Deal – Days After FDA IND Clearance for Rheumatoid Arthritis

Merck Launches Phase 3 ENHANCE‑3 Trial of OHTUVAYRE (Ensifentrine) – Targeting COPD Exacerbation Prevention

Merck Launches Phase 3 ENHANCE‑3 Trial of OHTUVAYRE (Ensifentrine) – Targeting COPD Exacerbation Prevention

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
RemeGen Inks Global Licensing Pact With Vor Bio for Telitacicept
HKG: 9995Rare / orphan disease drugs

RemeGen Inks Global Licensing Pact With Vor Biopharma for Telitacicept

Angel Pharma Gains NMPA Approval for Soquelitinib in Atopic Dermatitis Trial
Angel PharmaceuticalsClinical trial approval / initiation

Angel Pharma Gains NMPA Approval for Soquelitinib in Atopic Dermatitis Trial

Biogen's Phase I Results Highlight Salanersen's Potential in Spinal Muscular Atrophy
BiogenClinical trial results

Biogen’s Phase I Results Highlight Salanersen’s Potential in Spinal Muscular Atrophy

Kymera and Sanofi Advance IRAK4 Program With Selection of KT-485 for Clinical Development
Kymera TherapeuticsNASDAQ: KYMR

Kymera and Sanofi Advance IRAK4 Program With Selection of KT-485 for Clinical Development

Show More